Pediatrix Medical Group, Inc. (NYSE:MD) Given Consensus Recommendation of “Hold” by Analysts

Pediatrix Medical Group, Inc. (NYSE:MD) has received a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold rating. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $25.00.

A number of research analysts have recently commented on the stock. Jefferies Financial Group cut shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating and boosted their target price for the stock from $27.00 to $28.00 in a research report on Wednesday, August 19th. UBS Group raised their target price on Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, August 6th. Mizuho set a $24.00 price target on Pediatrix Medical Group in a report on Friday, May 8th. Truist Financial lifted their price objective on Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Finally, Weiss Ratings cut Pediatrix Medical Group from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 25th.

Institutional Investors Weigh In On Pediatrix Medical Group

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Global Retirement Partners LLC increased its holdings in shares of Pediatrix Medical Group by 68,250.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,367 shares of the company’s stock valued at $29,000 after acquiring an additional 1,365 shares during the last quarter. Transamerica Financial Advisors LLC acquired a new position in Pediatrix Medical Group in the fourth quarter worth $30,000. Eurizon Capital SGR S.p.A. acquired a new position in Pediatrix Medical Group in the fourth quarter worth $33,000. Nykredit A S acquired a new stake in shares of Pediatrix Medical Group during the second quarter worth $35,000. Finally, TD Private Client Wealth LLC bought a new position in shares of Pediatrix Medical Group in the 4th quarter worth about $39,000. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Price Performance

Shares of NYSE MD opened at $26.66 on Monday. Pediatrix Medical Group has a 1-year low of $15.69 and a 1-year high of $27.94. The business has a 50-day moving average of $26.06 and a 200-day moving average of $23.19. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.32 and a quick ratio of 1.32. The company has a market capitalization of $2.17 billion, a price-to-earnings ratio of 12.76 and a beta of 0.66.

Pediatrix Medical Group (NYSE:MD) last announced its earnings results on Tuesday, August 4th. The company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. The business had revenue of $487.78 million for the quarter, compared to the consensus estimate of $478.49 million. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The company’s revenue was up 4.1% on a year-over-year basis. During the same period last year, the business posted $0.53 EPS. On average, equities analysts anticipate that Pediatrix Medical Group will post 2.17 EPS for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.